Biomea Fusion (BMEA) AI Stock Analysis

• Market Cap: $93.93M
• Dividend Yield: N/A
• Average Volume (3M): 3.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: N/A
• EPS Growth: -10.99%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 37,572,250
• 10 Day Avg. Volume: 8,182,236
• 30 Day Avg. Volume: 3,172,879
• PEG Ratio: -0.05
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.89
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 9.21
• Enterprise Value/Gross Profit: 322.97
• Enterprise Value/Ebitda: -0.24
• 1Y Price Target: $13.60
• Price Target Upside: 421.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 35 Underperform
• Price Target: ―

Biomea Fusion's overall stock score is significantly impacted by its poor financial performance and bearish technical indicators. The company's inability to generate revenue and negative cash flows are major concerns, despite a low debt level. The technical analysis further highlights a negative trend, with the stock trading below key moving averages. Lastly, the lack of positive valuation metrics, such as a negative P/E ratio and absence of a dividend yield, further depresses the score.

Positive Factors

Clinical Trial Results

Biomea announced positive topline results from the Phase 2 COVALENT-111 clinical trial evaluating icovamenib in patients with T2D.

Efficacy of Treatment

Icovamenib exhibited a mean HbA1c reduction of 1.47% and a 53% increase in C-peptide after 14 weeks off-therapy, with no safety concerns.

Strategic Focus

Biomea plans to prioritize its metabolic disorders programs and become a diabetes- and obesity-focused company.

Negative Factors

Financial Position

The company ended the quarter with $36.2 million in cash, which management believes provides runway to fund ongoing operations until 4Q25.

Oncology Program Termination

The company announced a strategic refocus for icovamenib exclusively centered on metabolic disorders and terminated all ongoing oncology trials for the menin inhibitor candidate.

Organizational Changes

The company underwent a workforce reduction of approximately 35%, and consolidated all operations at a single facility.

Biomea Fusion Business Overview & Revenue Model

Company Description

Biomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers. The company operates within the healthcare sector, specializing in oncology. Biomea's core products revolve around its proprietary drug discovery platform, which aims to address unmet medical needs by targeting specific genetic mutations in cancer cells.

How the Company Makes Money

Biomea Fusion makes money through the development and eventual commercialization of its proprietary small molecule drug candidates. The company invests in research and development to advance its drugs through clinical trials. Revenue generation is primarily expected to occur upon successful commercialization of these drugs, either directly or through partnerships and licensing agreements with larger pharmaceutical companies. Additionally, Biomea may engage in strategic collaborations to co-develop treatments, which can provide milestone payments and royalties contingent upon the success of the drug candidates.

Biomea Fusion Financial Statement Overview

Summary

Biomea Fusion is facing significant challenges in financial performance, primarily due to its inability to generate revenue. The company's financial health is concerning, with increasing net losses and negative cash flows. The balance sheet offers some relief with low debt levels, but declining equity and negative operating cash flows pose substantial risks. The company needs to focus on revenue generation and cash flow management to improve its financial standing.

Income Statement

Biomea Fusion has struggled with consistent revenue generation, as evidenced by zero revenue across the years. The company's net losses have increased significantly, with the most recent annual report showing a net income of -$138 million. The absence of revenue highlights a critical challenge for the company, affecting profitability margins such as gross profit, EBIT, and EBITDA, all of which are negative.

Balance Sheet

The balance sheet indicates a relatively low debt-to-equity ratio, thanks to a modest amount of total debt compared to equity. However, the significant decline in equity from $169 million in 2023 to $51 million in 2024 raises concerns. High cash reserves compared to total debt suggest good liquidity, yet with shrinking equity, the financial stability is weakening.

Cash Flow

Operating cash flows have been deeply negative, with no signs of improvement. The free cash flow remains negative, but the drop in operating cash flow in 2024 to zero indicates a potential cash crunch. The inability to generate positive cash flow from operations is a key risk for the company's financial health.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.22M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
420.00K	0.00	-4.20M	-1.26M	-953.00K	-132.00K
	EBIT
-132.72M	-144.07M	-126.14M	-83.63M	-41.67M	-5.33M
	EBITDA
-131.40M	-136.68M	-124.62M	-82.94M	-41.42M	-5.32M
	Net Income Common Stockholders
-99.36M	-138.43M	-117.25M	-80.02M	-41.22M	-5.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
35.86M	58.28M	176.87M	113.40M	175.74M	61.70M
	Total Assets
55.05M	79.94M	199.93M	129.31M	185.71M	62.53M
	Total Debt
7.93M	8.77M	10.30M	2.29M	2.85M	259.00K
	Net Debt
-27.94M	-49.51M	-166.57M	-111.11M	-172.89M	-61.44M
	Total Liabilities
26.32M	28.36M	30.69M	20.77M	6.92M	57.36M
	Stockholders Equity
28.74M	51.57M	169.24M	108.54M	178.78M	5.17M
Cash Flow		Free Cash Flow
-113.86M	-120.26M	-99.96M	-63.45M	-38.61M	-4.51M
	Operating Cash Flow
-113.53M	-119.89M	-96.59M	-62.42M	-35.44M	-4.46M
	Investing Cash Flow
-327.00K	-362.00K	-2.22M	27.34M	-33.35M	-51.00K
	Financing Cash Flow
4.80M	1.67M	163.80M	1.24M	153.19M	65.97M

Biomea Fusion Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.61
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Neutral. The current price of 2.61 is above the 20-day moving average (MA) of 1.96, above the 50-day MA of 1.90, and below the 200-day MA of 5.04, indicating a neutral trend. The MACD of 0.21 indicates Negative momentum. The RSI at 56.54 is Neutral, neither overbought nor oversold. The STOCH value of 65.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMEA.

Biomea Fusion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
IVVD	44 Neutral	$101.58M	―	-122.69%	―	―	20.91%
LXEO	38 Underperform	$149.72M	―	-80.65%	―	―	-24.18%
ABOS	36 Underperform	$69.05M	―	-55.68%	―	―	-57.45%
BMEA	35 Underperform	$93.93M	―	-156.81%	―	―	-10.99%
UNCY	28 Underperform	$76.95M	―	-2355.27%	―	-100.00%	52.65%

Biomea Fusion Corporate Events

Biomea Fusion Appoints Interim CEO Amid Leadership Changes

On March 25, 2025, Biomea Fusion announced leadership changes with Dr. Michael J.M. Hitchcock appointed as interim CEO following Thomas Butler’s resignation. This transition is part of Biomea’s strategic efforts to advance its diabetes treatment pipeline, particularly after positive Phase II clinical results for icovamenib. The company is currently non-compliant with Nasdaq’s audit committee requirements due to a vacancy but plans to address this within the given cure period.

Biomea Fusion CFO Franco Valle Resigns

On February 24, 2025, Biomea Fusion announced the resignation of Franco Valle as Chief Financial Officer, effective March 7, 2025. The company clarified that Valle’s departure was amicable and unrelated to any financial or accounting issues, ensuring stakeholders of the company’s stable operational practices.